Company: MIRA
Filing Date: 2025-07-28
Form Type: 8-K
Source: 0001641172-25-021155
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

MIRA
Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U. S. Clinical Trials in Neuropathic Pain

Oral,
non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company
prepares to launch U. S. Phase 2a by year-end

MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that the U. S. Food and Drug Administration (FDA) has cleared its Investigational New Drug
(IND) application for Ketamir-2, the Company’s novel oral NMDA receptor antagonist for the treatment of neuropathic pain. The clearance
enables MIRA to initiate U. S.-based clinical trials.

The
IND submission included preclinical data demonstrating potent analgesic effects and a favorable safety profile across validated models
of diabetic, chemotherapy-induced, and nerve ligation-associated neuropathy. Ketamir-2 showed superior efficacy to gabapentin and pregabalin
in head-to-head studies and no evidence of ketamine-associated neurotoxicity.

Ketamir-2
achieved good oral bioavailability and efficient blood-brain barrier penetration, supported by its non-P-gp substrate status. Preclinical
studies further showed antidepressant- and anxiolytic-like effects with no dissociative or psychotomimetic side effects.

The
Company is nearing completion of the single ascending dose (SAD) portion of its international Phase 1 trial and is preparing to initiate
the multiple ascending dose (MAD) portion. MIRA plans to initiate its U. S.-based Phase 2a efficacy trial in the fourth quarter of 2025.

In
addition, MIRA continues to advance two other key programs. The Company’s planned acquisition of SKNY Pharmaceuticals, Inc. remains
on track, with SKNY-1 showing robust preclinical efficacy in obesity and nicotine craving models, as well as reversal of anxiety-like
behavior. Separately, MIRA-55, an oral cannabinoid analog, has demonstrated comparable efficacy to morphine in inflammatory pain models
and is under evaluation for further development.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     M